IPCA Laboratories · NSE: IPCALAB · BSE: 524494

Q1 FY21 results · Apr–Jun 2020

IPCA Laboratories reported revenue from operations of ₹1,534.40 crore (up 42.3% from Q1 FY20) and net profit of ₹445.68 crore (up 244.3% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	1,534.40	1,078.19	+42.3%	1,073.76	+42.9%
Other income	12.09	20.34	−40.6%	13.73	−11.9%
Total income	1,546.49	1,098.53	+40.8%	1,087.49	+42.2%
Profit before share of associates & JVs and tax	546.64	168.37	+224.7%	114.58	+377.1%
Share of profit/(loss) of associates & JVs	(1.07)	(1.59)		(2.33)
Net profit for the period	445.68	129.43	+244.3%	83.05	+436.6%
Attributable to shareholders of the company	446.13	129.63	+244.2%	86.01	+418.7%
EPS, basic (₹)	35.27	10.24	+244.4%	6.57	+436.8%
Net margin (%)	29.0	12.0		7.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	1,485.25	1,011.01	+46.9%	1,004.79	+47.8%
Other income	11.68	19.43	−39.9%	13.30	−12.2%
Total income	1,496.93	1,030.44	+45.3%	1,018.09	+47.0%
Profit before tax	551.94	167.96	+228.6%	157.17	+251.2%
Net profit for the period	453.64	132.05	+243.5%	127.76	+255.1%
EPS, basic (₹)	35.90	10.45	+243.5%	10.11	+255.1%
Net margin (%)	30.5	13.1		12.7

Consolidated

Filed with BSE: 10 Aug 2020, 18:41 IST
Board meeting: 10 Aug 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Aug 2020, 18:41 IST
Board meeting: 10 Aug 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE